about
Incidence of adverse drug reactions in human immune deficiency virus-positive patients using highly active antiretroviral therapyNon-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerabilityBarriers to a cure for HIV in womenInfluence of adverse drug reactions on treatment success: prospective cohort analysis of HIV-infected individuals initiating first-line antiretroviral therapy in IndiaAdverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medicationIncidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire.Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseasesWomen experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis.CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations.Sex, age, race and intervention type in clinical studies of HIV cure: a systematic review.Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.Pharmacoepidemiology of antiretroviral drugs in a teaching hospital in Lagos, NigeriaIncidence and determinants of nevirapine and efavirenz-related skin rashes in West Africans: nevirapine's epitaph?Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men.How do outcomes compare between women and men living with HIV in Australia? An observational study.Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretroviralsEffects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients.Gender-specific considerations in the antiretroviral management of HIV-infected women.The Use of Protease Inhibitors in Pregnancy: Maternal and Fetal Considerations.Evaluation of a sex-based difference in the pharmacokinetics of digoxin.Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African womenRole of animal models in the study of drug-induced hypersensitivity reactionsSex differences in pharmacokinetics and toxicity of antiretroviral therapy.Socio-economic- and sex-related disparities in rates of hospital admission among patients with HIV infection in Ontario: a population-based study.Adverse effects of highly active antiretroviral therapy in developing countries.Toxicity-related antiretroviral drug treatment modifications in individuals starting therapy: a cohort analysis of time patterns, sex, and other risk factors.Caring for women living with HIV: gaps in the evidence.A model and risk score for predicting nevirapine-associated rash among HIV-infected patients: in settings of low CD4 cell counts and resource limitationGender differences in discontinuation of antiretroviral treatment regimens.Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi.Effectiveness and metabolic complications after 96 weeks of a generic fixed-dose combination of stavudine, lamivudine, and nevirapine among antiretroviral-naive advanced HIV-infected patients in Thailand: A prospective study.Idiosyncratic reactions and metabolism of sulfur-containing drugs.HLA and pharmacogenetics of drug hypersensitivity.Bioactivation of drugs in the skin: relationship to cutaneous adverse drug reactions.Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.Implications of sulfotransferase activity in interindividual variability in drug response: clinical perspective on current knowledge.Sex-specific differences in treatment outcomes for patients with HIV and AIDS.Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions.Adverse Drug Reactions and Clinical Outcomes in Patients Initiated on Antiretroviral Therapy: A Prospective Cohort Study From Ethiopia.
P2860
Q24609339-6E8EFDE6-99CA-4871-B1B1-FE5DAEFFD8A5Q24628212-FD154393-0D2F-4A02-8063-BC58A71F7BB9Q26768632-3D00552B-8F43-425B-A207-298FBDB80BEDQ28540682-4416AE46-8821-4E75-A154-94C707ACD18AQ28749406-88EFE0B2-F979-4AF2-8AC9-480E9B753FE5Q33615251-35F41ECA-BBC4-4D2E-813F-6831D74C8C62Q33949316-BB52B876-3F21-46B9-BFD4-0306F0260863Q33997400-847A72E5-1E6D-4AB3-81C4-FB498D2DBF2CQ34148055-2F278893-EDCB-4B44-AF3C-8FAE93BCEFECQ34495636-8177517A-1A4E-411E-A527-0AB5C451D176Q34870233-252200D9-9AAC-400F-B89C-0C3E6D3C41A9Q35093189-6ADF5C58-E268-4C79-BDBE-1E109227E13CQ35104583-6008E7D6-538A-480E-80FD-EC901E838A07Q35146943-011FB284-0E08-4340-84FF-48C70FE5BDCDQ35885251-F3126A48-21CD-47BD-9DC2-2687E948C23DQ35908984-7790B565-84DB-4DA2-B5F9-6F649FA39A2DQ36073787-7BE3A157-12AF-4778-AF2C-9C21FEC43C09Q36074119-3A04CFEB-74FF-4B9F-B817-A773EE1358E1Q36140662-14628E46-0953-40C1-A153-5459808BC3B5Q36296422-9FA82C8A-3E6B-4A7D-A64A-F52F94C56AB9Q36410175-55824FFF-3EDF-44A6-A0EB-4495235C448AQ36422444-1C4AC69F-2C68-416C-9094-06708D018CBAQ36440385-18B03626-384D-4BB6-B331-7DCE124347FDQ36546272-927B9D40-5746-4141-A9FF-618DEA7554DFQ36845581-5CC146C7-3147-478F-9CBA-DEAD8246D398Q36945761-D2B1E06B-3D6C-419E-8F46-88805D790F82Q36954711-FF8A56B8-02EA-4558-8D22-8B84ECB281B5Q37212049-E7CBF3AE-39F6-42A9-BBAE-ABB1EAE8D4B8Q37271902-3AFBB754-2147-49A6-B4F3-94C5AF579085Q37440855-F10D7F66-6B73-4FF0-A04A-82C9AF2D5F82Q37544678-AD3EA523-996E-4B4C-92B9-A0FF8D3CBD2AQ37672806-6B4C52E1-47C9-4730-8FBF-403806464F04Q37991021-E9F5D9CB-9D8B-40F2-85D8-20402AA9A676Q38037649-DB830EAF-4A7B-40A8-A6F1-96530972DF45Q38155921-DC3D7E80-0F67-47CE-BA0F-B4A72B6C1BB6Q38853255-492787C0-76D5-41F8-B3AC-46E2F18D8491Q39336170-81E48FF6-A7F6-4E42-BD2B-9A2337954E1AQ40129396-4AB778EC-9316-4180-9E34-D85C03AA8B81Q40191483-BEEE3830-126E-4EF3-8654-8CC46BC5FCC1Q41203661-6E371BC9-F1F1-4D73-8BE4-BBB74BE131E3
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Sex differences in nevirapine rash.
@ast
Sex differences in nevirapine rash.
@en
type
label
Sex differences in nevirapine rash.
@ast
Sex differences in nevirapine rash.
@en
prefLabel
Sex differences in nevirapine rash.
@ast
Sex differences in nevirapine rash.
@en
P2093
P2860
P356
P1476
Sex differences in nevirapine rash.
@en
P2093
Bersoff-Matcha SJ
Hamrick Jr HJ
Powderly WG
van Der Horst C
P2860
P304
P356
10.1086/317536
P407
P577
2000-12-13T00:00:00Z